Primaquine pharmacokinetics in lactating women and breastfed infant exposures
Primaquine is the only drug providing radical cure of Plasmodium vivax malaria. It is not recommended for breastfeeding women as it causes hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals, and breast milk excretion and thus infant exposure are not known.Healthy G6PD normal...
| Prif Awduron: | , , , , , , , , , , , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
Oxford University Press
2018
|
| _version_ | 1826268399925198848 |
|---|---|
| author | Gilder, M Hanpithakphong, W Hoglund, R Tarning, J Win, H Hilda, N Chu, C Bancone, G Carrara, V Singhasivanon, P White, N Nosten, F McGready, R |
| author_facet | Gilder, M Hanpithakphong, W Hoglund, R Tarning, J Win, H Hilda, N Chu, C Bancone, G Carrara, V Singhasivanon, P White, N Nosten, F McGready, R |
| author_sort | Gilder, M |
| collection | OXFORD |
| description | Primaquine is the only drug providing radical cure of Plasmodium vivax malaria. It is not recommended for breastfeeding women as it causes hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals, and breast milk excretion and thus infant exposure are not known.Healthy G6PD normal breastfeeding women with previous P.vivax infection and their healthy G6PD normal infants between 28 days and 2 years old were enrolled. Mothers took primaquine 0.5 mg/kg/day for 14 days. Primaquine and carboxyprimaquine concentrations were measured in maternal venous plasma, capillary plasma, and breast milk samples and infant capillary plasma samples taken on days 0, 3, 7, and 13.In 20 mother-baby pairs primaquine concentrations were below measurement thresholds in all but one infant capillary plasma sample (that contained primaquine 2.6 ng/mL) and carboxyprimaquine was likewise unmeasurable in the majority of infant samples (maximum value 25.8 ng/mL). The estimated primaquine dose received by infants, based on measured breast milk levels, was 2.98 µg/kg/day (i.e. ~0.6% of a hypothetical infant daily dose of 0.5 mg/kg). There was no evidence of drug-related hemolysis in the infants. Maternal levels were comparable to non-lactating patients, and adverse events in mothers were mild.The concentrations of primaquine in breast milk are very low and therefore very unlikely to cause adverse effects in the breast-feeding infant. Primaquine should not be withheld from mothers breastfeeding infants or young children. More information is needed in neonates. |
| first_indexed | 2024-03-06T21:09:05Z |
| format | Journal article |
| id | oxford-uuid:3d8561b5-e38c-42dc-92e5-e378f2eaf397 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:09:05Z |
| publishDate | 2018 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:3d8561b5-e38c-42dc-92e5-e378f2eaf3972022-03-26T14:19:56ZPrimaquine pharmacokinetics in lactating women and breastfed infant exposuresJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3d8561b5-e38c-42dc-92e5-e378f2eaf397EnglishSymplectic Elements at OxfordOxford University Press2018Gilder, MHanpithakphong, WHoglund, RTarning, JWin, HHilda, NChu, CBancone, GCarrara, VSinghasivanon, PWhite, NNosten, FMcGready, RPrimaquine is the only drug providing radical cure of Plasmodium vivax malaria. It is not recommended for breastfeeding women as it causes hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals, and breast milk excretion and thus infant exposure are not known.Healthy G6PD normal breastfeeding women with previous P.vivax infection and their healthy G6PD normal infants between 28 days and 2 years old were enrolled. Mothers took primaquine 0.5 mg/kg/day for 14 days. Primaquine and carboxyprimaquine concentrations were measured in maternal venous plasma, capillary plasma, and breast milk samples and infant capillary plasma samples taken on days 0, 3, 7, and 13.In 20 mother-baby pairs primaquine concentrations were below measurement thresholds in all but one infant capillary plasma sample (that contained primaquine 2.6 ng/mL) and carboxyprimaquine was likewise unmeasurable in the majority of infant samples (maximum value 25.8 ng/mL). The estimated primaquine dose received by infants, based on measured breast milk levels, was 2.98 µg/kg/day (i.e. ~0.6% of a hypothetical infant daily dose of 0.5 mg/kg). There was no evidence of drug-related hemolysis in the infants. Maternal levels were comparable to non-lactating patients, and adverse events in mothers were mild.The concentrations of primaquine in breast milk are very low and therefore very unlikely to cause adverse effects in the breast-feeding infant. Primaquine should not be withheld from mothers breastfeeding infants or young children. More information is needed in neonates. |
| spellingShingle | Gilder, M Hanpithakphong, W Hoglund, R Tarning, J Win, H Hilda, N Chu, C Bancone, G Carrara, V Singhasivanon, P White, N Nosten, F McGready, R Primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| title | Primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| title_full | Primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| title_fullStr | Primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| title_full_unstemmed | Primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| title_short | Primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| title_sort | primaquine pharmacokinetics in lactating women and breastfed infant exposures |
| work_keys_str_mv | AT gilderm primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT hanpithakphongw primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT hoglundr primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT tarningj primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT winh primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT hildan primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT chuc primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT banconeg primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT carrarav primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT singhasivanonp primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT whiten primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT nostenf primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures AT mcgreadyr primaquinepharmacokineticsinlactatingwomenandbreastfedinfantexposures |